Position in VCEL
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$2,049,808
New position
Shares Held
63,718
first reported quarter
Ownership
0.125%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026HARBOR CAPITAL ADVISORS, INC. holds $23,126,231 across 27 Biotechnology names. VCEL ranks #4 (8.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KYMR |
Kymera Therapeutics, Inc.
|
33,948 | $2,827,528 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
30,353 | $2,639,800 | |
| 3 | TARS |
Tarsus Pharmaceuticals, Inc.
|
29,283 | $2,054,202 | |
| 4 | VCEL |
Vericel Corp
This page
|
63,718 | $2,049,808 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
31,355 | $2,026,473 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
83,196 | $1,742,956 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
80,085 | $1,742,649 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
43,005 | $1,454,859 |
All Filings in VCEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,049,808 | 63,718 | Shares | Sole | 2026-04-28 | |
| No filing history on record for this holder in this stock. | ||||||